A detailed history of Vanguard Group Inc transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Vanguard Group Inc holds 12,869,818 shares of ADPT stock, worth $46.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,869,818
Previous 12,767,684 0.8%
Holding current value
$46.6 Million
Previous $62.6 Million 33.97%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.88 - $4.8 $294,145 - $490,243
102,134 Added 0.8%
12,869,818 $41.3 Million
Q4 2023

Feb 14, 2024

BUY
$3.46 - $5.33 $1.79 Million - $2.76 Million
518,642 Added 4.23%
12,767,684 $62.6 Million
Q3 2023

Nov 14, 2023

BUY
$5.07 - $8.44 $996,533 - $1.66 Million
196,555 Added 1.63%
12,249,042 $66.8 Million
Q2 2023

Aug 14, 2023

BUY
$6.19 - $8.78 $464,701 - $659,140
75,073 Added 0.63%
12,052,487 $80.9 Million
Q1 2023

May 15, 2023

BUY
$7.8 - $10.11 $1.43 Million - $1.85 Million
183,246 Added 1.55%
11,977,414 $106 Million
Q4 2022

Feb 10, 2023

BUY
$6.26 - $9.34 $766,130 - $1.14 Million
122,385 Added 1.05%
11,794,168 $90.1 Million
Q3 2022

Nov 14, 2022

BUY
$6.5 - $12.67 $620,158 - $1.21 Million
95,409 Added 0.82%
11,671,783 $83.1 Million
Q2 2022

Aug 12, 2022

BUY
$6.4 - $14.73 $3.11 Million - $7.15 Million
485,540 Added 4.38%
11,576,374 $93.7 Million
Q1 2022

May 13, 2022

BUY
$10.12 - $28.9 $602,605 - $1.72 Million
59,546 Added 0.54%
11,090,834 $154 Million
Q4 2021

Feb 14, 2022

BUY
$25.17 - $36.85 $1.02 Million - $1.5 Million
40,615 Added 0.37%
11,031,288 $310 Million
Q3 2021

Nov 12, 2021

BUY
$30.02 - $39.87 $24.4 Million - $32.4 Million
813,014 Added 7.99%
10,990,673 $374 Million
Q2 2021

Aug 13, 2021

BUY
$32.22 - $44.59 $328 Million - $454 Million
10,177,659 New
10,177,659 $416 Million

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $517M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.